Current Updates in the Medical Management of Obesity

Author(s): Areej Khan, Shahzad Raza, Yusra Khan, Tulay Aksoy, Monis Khan, Yitzchak Weinberger, Joel Goldman

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 6 , Issue 2 , 2012


Obesity is a chronic medical condition that is expected to become an indirect but leading cause of mortality and morbidity. Obesity results in type 2 diabetes mellitus, insulin resistance, hypertension, dyslipidemia, coronary heart disease. These factors contribute to cardiovascular disease that is a leading cause of death. Therefore, the approach to obesity therapy should be designed to reduce cardiovascular disease risk and mortality. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but the resultant weight loss is often small. For more effective weight loss, individuals have shown to benefit from anti-obesity medications. Anti-Obesity therapy is considered for individuals with a body mass index greater than 30 kg/m2 or ranging from 25 to 30 kg/m2, or individuals with co-morbid conditions. Recent anti-obese medications affect biological mechanisms that suppress appetite and absorb nutrients to regulate body weight. In this review, we discuss the FDA approved anti-obesity drugs and recent patents which include phentermine/topiramate, pramlintide, lorcaserin, AOD9604, oleoyl-estrone, trk-beta antagonists and melanin concentrating hormone that can reduce adiposity at the molecular level.

Keywords: Exenatide, metabolic syndrome, phentermine, pramlintide, orlistat, topiramate, Diabetes, endocannabinoid system, Melanin Concentrating Hormone

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 09 May, 2012
Page: [117 - 128]
Pages: 12
DOI: 10.2174/187221412800604644
Price: $65

Article Metrics

PDF: 29